linjc16/ctgov huggingface dataset:
Role of BCL-B in Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
MM accounts for 10% of hematopoietic malignancies. Despite the use of various drug combinations in chemotherapy, life expectancy of MM patients does not exceed 7 years. Until now, lack of specific markers of the disease has not allowed efficient specific molecular targeting. In view of our preliminary results, the antiapoptotic protein Bcl-B could be a novel diagnostic and pronostic marker of MM. Therefore, our main objective will be to confirm that Bcl-B is indeed a novel diagnostic and pronostic marker and a new potential therapeutic target of MM. Targeting Bcl-2 family member's is a promising strategy for the treatment of hematopoietic malignancies. In this context, specific targeting of Bcl-B could improve the treatment of patients suffering MM. Of note, this could be achieved by converting the antiapoptotic function of Bcl-B to a proapoptotic one thanks to the use of small mimetic peptides derived from Nur77 one of its interactors.

Official Title
-----------------
Implication of the Antiapoptotic Protein BCL-B in the Pathogenesis of Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with Multiple Myeloma and MGUS newly diagnosed at the Service de Medecine Interne-Cancerologie department of the Nice CHU

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine whether BCL-B is a survival factor in malignant plasmocytes, we will analyse the level of expression of Bcl-B at the both mRNA and protein levels in a cohort of MGUS and MM patients. | To determine whether BCL-B is a survival factor in malignant plasmocytes,we will analyse the level of expression of Bcl-B at the both mRNA and protein levels in a cohort of MGUS and MM patients. The implication of Bcl-B in malignant plasmocyte survival will be evaluated by loss of fucntion experiments (Si-RNA). This will also allow to determine whether Bcl-B is involved in the MGUS to MM transition. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine whether deregulation of BCL-B expression is associated to chimioresistances commonly observed in Multiple Myeloma, We will compare Bcl-B expression in MM patients either sensitive or resistant to conventional therapies. | To determine whether deregulation of BCL-B expression is associated to chimioresistances commonly observed in Multiple Myeloma, We will compare Bcl-B expression in MM patients either sensitive or resistant to conventional therapies. We will focuse on resistance to Velcade. we have also isolated established MM cell lines resistant to velcade in vitro which will be useful for the study with MM patients samples. | 6 months |
Surgically Induced Astigmatism of Temporal Versus Nasal Clear Corneal Phacoemulsification

Study Overview
=================
Brief Summary
-----------------
To compare the short-term astigmatic outcomes of phacoemulsification cataract surgery and intraocular lens implantation using temporal versus nasal clear corneal incisions.

Detailed Description
-----------------
In a clinical trial, consecutive eyes with senile cataract underwent phacoemulsification with implantation of a 6.0 mm foldable hydrophobic acrylic intraocular lens through a 3.2 mm horizontal clear cornea incision at 180 degrees (temporal incision in right eyes, nasal incision in left eyes). Keratometric astigmatism was measured preoperatively and one and four weeks and 6 months after surgery. Surgically induced astigmatism (SIA) was calculated by the vector analysis method using the Holladay-Cravy-Koch formula. Patients with history of diabetes mellitus, connective tissue disorders, steroid use, previous ocular surgery, with the rule astigmatism >1D, pseudoexfoliation and any corneal pathology were excluded.

Conditions
-----------------
Surrgical Induced Astigmatism

Intervention / Treatment
-----------------
* Procedure: phacoemulsification and intraocular lens implantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the patients with senile cataract Exclusion Criteria: Previously operated eyes Presence of corneal pathology Pseudo exfoliation With-the-rule (WTR) astigmatism >1 D Presence of diabetes mellitus History of connective tissue disease Consumption of systemic steroids
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Temporal (right eye) | Procedure: phacoemulsification and intraocular lens implantation<br>* clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively<br>|
| Experimental: 2<br>Nasal (Left eye) | Procedure: phacoemulsification and intraocular lens implantation<br>* clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total and Surgical Induced Astigmatism |  | At 1 and 4 weeks and 6 month after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kataract, Astigmatism, phacoemulsification
Treatment for Borderline Personality Disorder

Study Overview
=================
Brief Summary
-----------------
This study will expose patients to either a Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) to determine the more effective therapy for treating borderline personality disorder.

Detailed Description
-----------------
Participants are randomly assigned to receive either Systems Training for Emotional Predictability and Problem Solving (STEPPS) or treatment as usual (TAU) for 20 weeks. STEPPS is a new cognitive behavioral treatment which involves skills training for emotion management and lifestyle behaviors as well as education for the affected individual's family members, friends, and professional caregivers. Participants are assessed at baseline and Weeks 4, 8, 12, 16, and 20. Interviews of patient's health care providers and family members and self-rating scales are used to assess patients. Follow-up assessments are made 1, 3, 6, 9, and 12 months after study completion. Participants must live within a reasonable driving distance of Iowa City, IA.

Official Title
-----------------
A Cognitive Group Treatment for Borderline Outpatients

Conditions
-----------------
Borderline Personality Disorder

Intervention / Treatment
-----------------
* Behavioral: Systems Training for Emotional Predictability and Problem Solving (STEPPS)
* Behavioral: Treatment As Usual (TAU)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Borderline Personality Disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: STEPPS<br>Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes | Behavioral: Systems Training for Emotional Predictability and Problem Solving (STEPPS)<br>* STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.<br>|
| Placebo Comparator: Treatment as Usual<br>Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes. TAU for this BPD population includes medical management, group and individual therapy. | Behavioral: Treatment As Usual (TAU)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluation of Neutrophil/Lymphocyte Ratio ,Platelet/Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia

Study Overview
=================
Brief Summary
-----------------
Evaluation of neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP as markers of severity of Pre-eclampsia

Official Title
-----------------
Evaluation of Neutrophil/Lymphocyte Ratio, Platelet /Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia

Conditions
-----------------
Pre-Eclampsia

Intervention / Treatment
-----------------
* Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - PREECLAMPSIA from 25_45years Exclusion Criteria: chronic diseases Primary hypertension

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Neutrophil/lymphocyte ratio<br> | Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP<br>* Lab<br>|
| Other: Platelet/lymphocyte ratio<br> | Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP<br>* Lab<br>|
| Other: CRP<br> | Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP<br>* Lab<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PREECLAMPSIA |  | 6months |
Amphetamine Cocaine Interaction Study - 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate results of d-amphetamine - cocaine (pharmacology) interaction study.

Official Title
-----------------
Amphetamine Cocaine Interaction Study

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Dextroamphetamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dextroamphetamine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Waist Circumference Measurements in Schizophrenic Patients

Study Overview
=================
Brief Summary
-----------------
The prevalence of metabolic syndrome(MS) among pt's with schizophrenia has been reported to be high, ranging from 24 to 43% in males and 27 to 52% in females. Schizophrenic patients with MS have an increased incidence of DM, coronary heart disease and increased mortality from cardiovascular diseases. Central adiposity is highly correlated with the presence of hypertension, coronary heart disease, type 2 diabetes, and increased mortality risk. Waist circumference(WC) is a better indicator of abdominal obesity and a better predictor of CVD than either BMI or waist-to-hip ratio. However, currently there is no standard location for the measurement of WC. Objectives: 1. To compare the magnitude of WC measured at 3 sites ( immediately above the iliac crest, midpoint between the lowest rib and the iliac crest , umbilical level) in males and females. 2. To examine the correlation of WC with Triglyceride, cholesterol, HDL, LDL and glucose.

Official Title
-----------------
Variability of Waist Circumference Measurements at 3 Sites and Its Relationship With Cardiovascular Risk Factors in Patients With Schizophrenia

Conditions
-----------------
Waist Circumference Measurements, Schizophrenia, Cardiovascular Risk Factor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Patients with schizophrenia or schizoaffective disorder (DSM-IV 295) age 18 till 65 years old. Body weight change less than 1 kg in previous one month before index date. Exclusion Criteria: • Patients with a previous hyperlipidemia diagnosis or antilipemic prescription during the preceding 30 days. Patients received any anti-hypertensives or oral hypoglycemic agents. Pregnant or breast-feeding women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Open Study to Evaluate the Performance of Dressing on Subject With High Risk of Skin Breakdown

Study Overview
=================
Brief Summary
-----------------
The rational for the study is to add a thin self-adherent dressing on critically ill patients. Evaluate if the dressing might protect the skin for further breakdown.Participants will be followed for the duration of hospital stay, an expected average of 5 days.

Official Title
-----------------
A Multi-Centre, Post CE Mark, Open Study to Evaluate the Performance of Thin Self-adherent Dressing Coated With a Soft Silicone Layer on Subjects With a High Risk of Skin Breakdown

Conditions
-----------------
Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of written informed consent Braden total score ≤ 12 at enrolment Male or female, ≥ 18 at enrolment No skin- breakdown Subject or family member is able to understand and comply with the requirements of the study, judged by the investigator Exclusion Criteria: Risk area dosen´t fit the dressing size Documented skin disease Kown allergy to any of the components in the dressing Previous enroled in present study Subject included in other ongoing clinical investigation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Erythema (No/Yes) | Measure number of skin breakdown during from enrolment to termination. | During 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Experience of Use of the Dressing | Overall experience of use of the dressing rated on a scale from Very Poor, Poor, Good, Very Good, Excellent | During 5 days |
Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus

Study Overview
=================
Brief Summary
-----------------
Single center, open label crossover study with 2 treatment phases in healthy volunteers. The potential of phenotypic drug probes to predict drug-drug interactions between tacrolimus, voriconazole and rifampin will be assessed.

Official Title
-----------------
Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus

Conditions
-----------------
Drug Interactions, Kidney Transplantation

Intervention / Treatment
-----------------
* Drug: Voriconazole
* Drug: Rifampin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male Age over 18 years Written informed consent Exclusion Criteria: Female Medical comorbidities Use of concomitant medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Voriconazole<br>Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6. | Drug: Voriconazole<br> <br> * Other names: Vfend;|
| Experimental: Rifampin<br>Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13. | Drug: Rifampin<br> <br> * Other names: Rifadin; Rifadine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in tacrolimus area under the curve | assessed twice: once after each treatment | 2 weeks |
Sub Urethral Sling With or With Out Anterior Repair

Study Overview
=================
Brief Summary
-----------------
There is a concern about choosing adequate surgical options for stress urinary incontinence associated with vaginal prolapsed and still lack of evidence can be observed. In this study we compared primary and secondary outcomes of single or combine surgery for SUI with pelvic organ prolapsed.

Official Title
-----------------
a Retrospective Cohort Recognize the Out Comes of SUS With or Without Anterior Vaginal Repair

Conditions
-----------------
Urinary Incontinence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be female Subjective evidence of stress predominant symptoms on symptom specific questionnaire Stress incontinence on urodynamics Patients must be capable of filling in the symptom diary Prolapse beyond the introitus Exclusion Criteria: Patients who are medically unfit to undergo surgical intervention. Patients who have undergone previous continence surgery Patients with voiding dysfunction Patients with recurrent urinary tract infection Patients who are not sure that their family is complete

Ages Eligible for Study
-----------------
Minimum Age: 27 Years
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sub urethral sling<br> | |
| sus with anterior vainal wall repair<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary incontinence cure rate according ICIQ-UIsf |  | 3 month after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| morbidity and complication |  | 3 month after surgery |
The Efficacy of Acacia Catechu Mouthrinse as Antiplaque and Antigingivitis Agent in Fixed Orthodontic Appliance Patients.

Study Overview
=================
Brief Summary
-----------------
To study effect of acacia catechu a herbal extract;as antipaque and antigingivitis agent in patients with fixed orthodontic appliances.This study is a double blind randomized controlled trial.

Conditions
-----------------
Gingivitis

Intervention / Treatment
-----------------
* Drug: Acacia catechu
* Drug: Chlorhexidine gluconate
* Other: Distilled water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 60 patients in the age group of 15-30 yrs plaque induced gingivitis having fixed orthodontic appliance Exclusion Criteria: seeking any type of antibacterial mouthwash within four weeks of commencement of study, history of any systemic disease, or past illness, mentally or physically handicapped, history of smoking, tobacco chewing, alcohol consumption, patients with periodontitis, pregnant and lactating women

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acacia<br>Rinse with 20 ml of Acacia catechu mouthwash twice daily for 15 days | Drug: Acacia catechu<br> <br> Drug: Chlorhexidine gluconate<br> <br> * Other names: Hexidine;Other: Distilled water<br> <br> |
| Active Comparator: Chlorhexidine gluconate<br>Rinse with 10 ml of chlorhexidine mouthwash twice daily for 15 days | Drug: Acacia catechu<br> <br> Drug: Chlorhexidine gluconate<br> <br> * Other names: Hexidine;Other: Distilled water<br> <br> |
| Placebo Comparator: Distilled water<br>Rinse with 10 ml distilled water twice daily for 15 days. | Drug: Acacia catechu<br> <br> Drug: Chlorhexidine gluconate<br> <br> * Other names: Hexidine;Other: Distilled water<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline in Plaque index(PI) |  | 15 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline in Gingival index(GI) |  | 15 Days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acacia, Chlorhexidine, Gingivitis, Orthodontic appliances.